The Relationship between Health Insurance and Pharmaceutical Innovation: An Empirical Study Based on Meta-Analysis

被引:1
作者
Fan, Chenchen [1 ]
Song, Xiaoting [1 ]
Li, Chunyan [1 ]
机构
[1] Tongji Univ, Shanghai Int Coll Intellectual Property, Shanghai 200092, Peoples R China
关键词
health insurance; pharmaceutical innovation; meta-analysis; effect size; MEDICARE PART-D; MARKET-SIZE; COVERAGE; PRICE; LINK;
D O I
10.3390/healthcare11222916
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The growing research interest in the relationship between health insurance and pharmaceutical innovation is driven by their significant impact on healthcare optimization and pharmaceutical development. The existing literature, however, lacks consensus on this relationship and provides no evidence of the magnitude of a correlation. In this context, this study employs meta-analysis to explore the extent to which health insurance affects pharmaceutical innovation. It analyzes 202 observations from 14 independent research samples, using the regression coefficient of health insurance on pharmaceutical innovation as the effect size. The results reveal that there is a strong positive correlation between health insurance and pharmaceutical innovation (r = 0.367, 95% CI = [0.294, 0.436]). Public health insurance exhibits a stronger promoting effect on pharmaceutical innovation than commercial health insurance. The relationship between health insurance and pharmaceutical innovation is moderated by the country of sample origin, data range, journal type, journal impact factor, type of health insurance, and research perspective. Our research findings further elucidate the relationship mechanism between health insurance and pharmaceutical innovation, providing a valuable reference for future explorations in pharmaceutical fields.
引用
收藏
页数:18
相关论文
共 61 条
  • [31] Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO
  • [32] 2-D
  • [33] Hunter JE., 2004, Methods of meta-analysis: Correcting error and bias in research findings, V2, DOI [10.4135/9781412985031, DOI 10.4135/9781412985031]
  • [34] The impact of public performance reporting on health plan selection and switching: A systematic review and meta-analysis
    Kelaher, Margaret
    Prang, Khic-Houy
    Sabanovic, Hana
    Dunt, David
    [J]. HEALTH POLICY, 2019, 123 (01) : 62 - 70
  • [35] Khayatan M., 2008, Ph.D. Thesis
  • [36] How to make value-based health insurance designs more effective? A systematic review and meta-analysis
    Krack, Gundula
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (06) : 841 - 856
  • [37] Pharmaceutical advertising and Medicare Part D
    Lakdawalla, Darius
    Sood, Neeraj
    Gu, Qian
    [J]. JOURNAL OF HEALTH ECONOMICS, 2013, 32 (06) : 1356 - 1367
  • [38] Economics of the Pharmaceutical Industry
    Lakdawalla, Darius N.
    [J]. JOURNAL OF ECONOMIC LITERATURE, 2018, 56 (02) : 397 - 449
  • [39] The primary health-care system in China
    Li, Xi
    Lu, Jiapeng
    Hu, Shuang
    Cheng, K. K.
    De Maeseneer, Jan
    Meng, Qingyue
    Mossialos, Elias
    Xu, Dong Roman
    Yip, Winnie
    Zhang, Hongzhao
    Krumholz, Harlan M.
    Jiang, Lixin
    Hu, Shengshou
    [J]. LANCET, 2017, 390 (10112) : 2584 - 2594
  • [40] How many life-years have new drugs saved? A three-way fixed-effects analysis of 66 diseases in 27 countries, 2000-2013
    Lichtenberg, Frank R.
    [J]. INTERNATIONAL HEALTH, 2019, 11 (05): : 403 - 416